ZZVET / SHUTTERSTOCK.COM
The battle between pharmaceutical and generics companies in India is once again in the spotlight, with a decision pending on another compulsory licence. The players this time are Novartis and Cipla, with the former already having drawn first blood. LSIPR investigates.
The last 12 months have brought a lot of change in India. First, a new government, the Bharatiya Janata Party, was voted into office in May 2014 and said straight away it would be focusing on, among other things, intellectual property.
Then, shortly after the election, Nirmala Sitharaman, the new commerce and industry minister, said India would “constructively engage” with the US—a long-term critic of its IP regime—about it.
The US Trade Representative’s annual Special 301 Report had included India on its ‘priority watch list’ (the report assesses US trading partners’ efforts to protect IP, and was released a few weeks before the general election). However, these two developments suggested that fears concerning India’s patent laws, particularly those surrounding pharmaceuticals, might soon be addressed.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Novartis, Cipla, Inidan Patent Office, Onbrez, compulsory licence, Delhi High Court
